450 related articles for article (PubMed ID: 16606763)
1. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Hedera P; Kluin KJ; Carlson M; Askari F; Dick RB; Sitterly J; Fink JK
Arch Neurol; 2003 Mar; 60(3):379-85. PubMed ID: 12633149
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Johnson V; Dick RD; Kluin KJ; Fink JK; Brunberg JA
Arch Neurol; 1996 Oct; 53(10):1017-25. PubMed ID: 8859064
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.
Askari FK; Greenson J; Dick RD; Johnson VD; Brewer GJ
J Lab Clin Med; 2003 Dec; 142(6):385-90. PubMed ID: 14713890
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of neurologic examination findings in Wilson disease.
Burke JF; Dayalu P; Nan B; Askari F; Brewer GJ; Lorincz MT
Parkinsonism Relat Disord; 2011 Aug; 17(7):551-6. PubMed ID: 21641265
[TBL] [Abstract][Full Text] [Related]
8. [New possibilities in the treatment of Wilson-Konovalov disease (hepatolenticular degeneration)].
Kolarski V
Vutr Boles; 1987; 26(5):37-40. PubMed ID: 3433729
[TBL] [Abstract][Full Text] [Related]
9. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment.
Arnon R; Calderon JF; Schilsky M; Emre S; Shneider BL
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):596-602. PubMed ID: 17460493
[TBL] [Abstract][Full Text] [Related]
10. Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy.
Fukuda H; Ebara M; Okabe S; Yoshikawa M; Sugiura N; Saisho H; Kondo F; Yukawa M
J Lab Clin Med; 2004 Jun; 143(6):333-9. PubMed ID: 15192648
[TBL] [Abstract][Full Text] [Related]
11. Wilson disease: genetic basis of copper toxicity and natural history.
Schilsky ML
Semin Liver Dis; 1996 Feb; 16(1):83-95. PubMed ID: 8723326
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of Wilson disease].
Smolarek C; Stremmel W
Z Gastroenterol; 1999 Apr; 37(4):293-300. PubMed ID: 10378366
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
[TBL] [Abstract][Full Text] [Related]
14. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
[TBL] [Abstract][Full Text] [Related]
15. Trientine-induced neurological deterioration in a patient with Wilson's disease.
Kim B; Chung SJ; Shin HW
J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism.
Shimizu N; Fujiwara J; Ohnishi S; Sato M; Kodama H; Kohsaka T; Inui A; Fujisawa T; Tamai H; Ida S; Itoh S; Ito M; Horiike N; Harada M; Yoshino M; Aoki T
Transl Res; 2010 Dec; 156(6):350-7. PubMed ID: 21078496
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
18. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.
Medici V; Sturniolo GC
IDrugs; 2008 Aug; 11(8):592-606. PubMed ID: 18683094
[TBL] [Abstract][Full Text] [Related]
19. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients.
Linn FH; Houwen RH; van Hattum J; van der Kleij S; van Erpecum KJ
Hepatology; 2009 Nov; 50(5):1442-52. PubMed ID: 19731238
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]